China NT Pharma Group Company Limited (HKG:1011)
0.670
+0.020 (3.08%)
Apr 29, 2026, 3:38 PM HKT
HKG:1011 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 7.22 | 9.62 | 1.52 | 5.93 | 9.44 | Upgrade
|
| Cash & Short-Term Investments | 7.22 | 9.62 | 1.52 | 5.93 | 9.44 | Upgrade
|
| Cash Growth | -24.96% | 533.09% | -74.37% | -37.19% | 22.73% | Upgrade
|
| Accounts Receivable | 1.8 | - | 10.05 | 33.67 | 12.45 | Upgrade
|
| Other Receivables | 0.1 | 0.08 | 0.55 | 20.78 | 21.52 | Upgrade
|
| Receivables | 1.9 | 0.08 | 10.6 | 54.45 | 33.98 | Upgrade
|
| Inventory | 0.4 | 0.17 | - | 10.32 | 32.01 | Upgrade
|
| Prepaid Expenses | - | 5.02 | 0.11 | - | - | Upgrade
|
| Other Current Assets | 5.84 | 1.29 | 0.05 | 2.74 | 192.28 | Upgrade
|
| Total Current Assets | 15.36 | 16.19 | 12.28 | 73.43 | 267.7 | Upgrade
|
| Property, Plant & Equipment | 0.63 | 0.54 | 0.94 | 379.72 | 222.37 | Upgrade
|
| Long-Term Investments | 331.36 | 317.28 | 313.55 | 277.58 | 278.46 | Upgrade
|
| Other Intangible Assets | - | - | 0.2 | 274.98 | 186.83 | Upgrade
|
| Other Long-Term Assets | - | 0.07 | 2.16 | - | - | Upgrade
|
| Total Assets | 347.35 | 334.08 | 329.12 | 1,006 | 955.36 | Upgrade
|
| Accounts Payable | 2.66 | 2.22 | 5 | 8.48 | 44.63 | Upgrade
|
| Accrued Expenses | 130.43 | 143.99 | 118.64 | 170.56 | 100.1 | Upgrade
|
| Short-Term Debt | - | 313.81 | 286.09 | 348.07 | 140.45 | Upgrade
|
| Current Portion of Long-Term Debt | 316.13 | 53.69 | 54.62 | 476.97 | 476.38 | Upgrade
|
| Current Portion of Leases | 0.49 | 0.34 | 0.63 | 0.95 | 1.61 | Upgrade
|
| Current Income Taxes Payable | - | - | 0.12 | 25.05 | 13.98 | Upgrade
|
| Current Unearned Revenue | - | - | - | 4.8 | 6.1 | Upgrade
|
| Other Current Liabilities | 171.4 | 211.02 | 199.98 | 134.82 | 112.73 | Upgrade
|
| Total Current Liabilities | 621.1 | 725.07 | 665.09 | 1,170 | 895.97 | Upgrade
|
| Long-Term Debt | - | 7.99 | 3.22 | - | 213.29 | Upgrade
|
| Long-Term Leases | 0.09 | 0.13 | 0.38 | 0.46 | 0.39 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | - | 77.22 | 57.08 | Upgrade
|
| Total Liabilities | 621.18 | 733.18 | 668.69 | 1,247 | 1,167 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | - | 1,806 | 1,806 | 1,759 | 1,759 | Upgrade
|
| Retained Earnings | - | -2,549 | -2,498 | -2,639 | -2,537 | Upgrade
|
| Comprehensive Income & Other | -273.62 | 343.89 | 351.98 | 638.24 | 566.86 | Upgrade
|
| Total Common Equity | -273.62 | -399.11 | -339.57 | -241.66 | -211.38 | Upgrade
|
| Minority Interest | -0.21 | - | - | - | - | Upgrade
|
| Shareholders' Equity | -273.83 | -399.11 | -339.57 | -241.66 | -211.38 | Upgrade
|
| Total Liabilities & Equity | 347.35 | 334.08 | 329.12 | 1,006 | 955.36 | Upgrade
|
| Total Debt | 316.7 | 375.95 | 344.94 | 826.45 | 832.11 | Upgrade
|
| Net Cash (Debt) | -309.48 | -366.33 | -343.42 | -820.52 | -822.67 | Upgrade
|
| Net Cash Per Share | -0.50 | -1.39 | -1.44 | -4.32 | -4.35 | Upgrade
|
| Filing Date Shares Outstanding | 674.25 | 264.09 | 264.09 | 190.46 | 190.46 | Upgrade
|
| Total Common Shares Outstanding | 674.25 | 264.09 | 264.09 | 190.46 | 190.46 | Upgrade
|
| Working Capital | -605.73 | -708.88 | -652.81 | -1,096 | -628.27 | Upgrade
|
| Book Value Per Share | -0.41 | -1.51 | -1.29 | -1.27 | -1.11 | Upgrade
|
| Tangible Book Value | -273.62 | -399.11 | -339.76 | -516.64 | -398.21 | Upgrade
|
| Tangible Book Value Per Share | -0.41 | -1.51 | -1.29 | -2.71 | -2.09 | Upgrade
|
| Buildings | - | - | - | 363.03 | 207.26 | Upgrade
|
| Machinery | - | 0.02 | 0.16 | 87.27 | 38.16 | Upgrade
|
| Construction In Progress | - | - | - | 5.83 | 1.5 | Upgrade
|
| Leasehold Improvements | - | - | - | 9.73 | 9.25 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.